VIRI - Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Virios Therapeutics (VIRI) rises 10% premarket in reaction to the announcement it is collaborating with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome ((IBS)).The first step in the partnership is focused on designing a phase 2 proof of concept study to treat the pain associated with IBS, with long-term goal of conducting phase 2 study.The study will evaluate if IMC-1, a fixed dose antiviral combination of famciclovir and celecoxib, can play a role in addressing the pain associated with IBS.

For further details see:

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome